$204.49 Million in Sales Expected for Myriad Genetics, Inc. (MYGN) This Quarter
Brokerages forecast that Myriad Genetics, Inc. (NASDAQ:MYGN) will report sales of $204.49 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Myriad Genetics’ earnings. The lowest sales estimate is $201.60 million and the highest is $209.06 million. Myriad Genetics posted sales of $190.20 million during the same quarter last year, which would indicate a positive year over year growth rate of 7.5%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, November 6th.
On average, analysts expect that Myriad Genetics will report full year sales of $904.34 million for the current fiscal year, with estimates ranging from $884.60 million to $936.10 million. For the next fiscal year, analysts forecast that the business will post sales of $971.20 million, with estimates ranging from $920.00 million to $1.03 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Myriad Genetics.
Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, August 21st. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.05. Myriad Genetics had a return on equity of 9.78% and a net margin of 17.69%. The firm had revenue of $200.90 million during the quarter, compared to analyst estimates of $195.93 million. During the same period last year, the firm posted $0.30 EPS. The business’s revenue was up .7% compared to the same quarter last year.
Shares of Myriad Genetics stock traded down $0.19 during trading hours on Wednesday, hitting $43.50. 969,537 shares of the company’s stock traded hands, compared to its average volume of 733,741. Myriad Genetics has a 12-month low of $27.23 and a 12-month high of $50.44. The firm has a market cap of $3.26 billion, a PE ratio of 36.25, a P/E/G ratio of 3.12 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.19 and a quick ratio of 2.86.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Robecosam AG grew its holdings in Myriad Genetics by 39.8% during the 2nd quarter. Robecosam AG now owns 4,193 shares of the company’s stock valued at $156,000 after buying an additional 1,193 shares in the last quarter. Piedmont Investment Advisors LLC grew its holdings in Myriad Genetics by 1.9% during the 2nd quarter. Piedmont Investment Advisors LLC now owns 70,179 shares of the company’s stock valued at $2,623,000 after buying an additional 1,285 shares in the last quarter. Vident Investment Advisory LLC grew its holdings in Myriad Genetics by 1.5% during the 2nd quarter. Vident Investment Advisory LLC now owns 86,231 shares of the company’s stock valued at $3,222,000 after buying an additional 1,293 shares in the last quarter. Amalgamated Bank grew its holdings in Myriad Genetics by 14.0% during the 2nd quarter. Amalgamated Bank now owns 10,611 shares of the company’s stock valued at $397,000 after buying an additional 1,302 shares in the last quarter. Finally, CWM LLC boosted its position in shares of Myriad Genetics by 0.6% during the 2nd quarter. CWM LLC now owns 282,289 shares of the company’s stock valued at $10,549,000 after acquiring an additional 1,650 shares during the last quarter.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Further Reading: How is an ETF different from a mutual fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.